BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
1.990
-0.030 (-1.49%)
At close: Oct 30, 2026, 4:00 PM EDT
1.950
-0.040 (-2.01%)
After-hours: Oct 30, 2026, 4:10 PM EDT
BioLineRx Employees
As of December 31, 2025, BioLineRx had 24 total employees, including 20 full-time and 4 part-time employees. The number of employees decreased by 4 or 14.29% compared to the previous year.
Employees
24
Change (1Y)
-4
Growth (1Y)
-14.29%
Revenue / Employee
$58,000
Profits / Employee
-$291,208
Market Cap
9.50M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 24 | -4 | -14.29% | 20 | 4 |
| Dec 31, 2024 | 28 | -51 | -64.56% | 24 | 4 |
| Dec 31, 2023 | 79 | 30 | 61.22% | 79 | 0 |
| Dec 31, 2022 | 49 | 11 | 28.95% | 49 | 0 |
| Dec 31, 2021 | 38 | 0 | - | 38 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Palatin Technologies | 25 |
| Lisata Therapeutics | 21 |
| IN8bio | 18 |
| Lantern Pharma | 16 |
| CalciMedica | 15 |
| Kiora Pharmaceuticals | 13 |
| Tvardi Therapeutics | 12 |
| Purple Biotech | 10 |
BLRX News
- 8 days ago - BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 - PRNewsWire
- 23 days ago - BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day - PRNewsWire
- 5 weeks ago - BioLineRx files to sell 2.02M American Depositary Shares for holders - TheFly
- 5 weeks ago - BioLineRx Registration statement: Registration filing - Filings
- 7 weeks ago - BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) - PRNewsWire
- 2 months ago - BioLineRx Releases Q2 2026 Financial Results - AlphaStreet
- 2 months ago - BioLineRx Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - BioLineRx Earnings release: Q2 2026 - Filings